News and
Investors

Filter
Sort by Date

Press Release

Walden Biosciences to Host Virtual Event on November 14, 2023 “Transforming the Treatment Landscape of Chronic Kidney Disease”

November 7, 2023

Press Release

Walden Biosciences Announces First Subject Dosed in First-in-Humans Phase 1 Clinical Trial of WAL0921, in Development for Treatment of Chronic Kidney Diseases

June 5, 2023

Press Release

Walden Biosciences Promotes Curt Dewan, CFA to Chief Financial Officer

April 5, 2023

Press Release

Walden Biosciences Announces Presentation at the Oppenheimer 33rd Annual Healthcare Conference

March 9, 2023

Press Release

Walden Biosciences To Present at 5th Annual Chronic Kidney Disease Drug Development Summit

March 8, 2023

Press Release

Walden Biosciences Announces Presentation at Antibody Engineering and Therapeutics Conference 2022

December 2, 2022